Table 3

Logistic regression analysis to determine the prognostic effects of selected variables on vision maintenance (loss of <15 letters) at (A) year 1 and (B) year 2

	Coefficient	SE	Lower 95% CI	Upper 95% CI	p Value
(A) Variables (year 1)
Country
Canada	1.25	1.32	0.16	9.85	0.83
France	0.71	0.74	0.09	5.42	0.74
Germany	0.78	0.82	0.10	6.12	0.82
Ireland	1.66	1.86	0.19	14.91	0.65
Italy	0.91	0.94	0.12	6.91	0.93
The Netherlands	1.22	1.27	0.16	9.40	0.85
UK	1.21	1.27	0.15	9.43	0.86
Reimbursement type
Individual	0.71	0.23	0.38	1.33	0.28
National standard	0.79	0.19	0.49	1.26	0.32
Separate contract	0.40	0.31	0.09	1.82	0.23
Patient	0.73	1.28	0.02	22.90	0.86
Unknown	1.41	0.89	0.41	4.87	0.59
Other	0.57	0.62	0.07	4.73	0.60
Age at start of therapy	0.97	0.01	0.95	0.98	<0.001
Baseline visual acuity score	0.97	0.00	0.96	0.98	<0.001
Number of injections (ranibizumab)	0.94	0.03	0.88	0.99	0.03
Switch to other treatments	0.86	0.23	0.51	1.44	0.56
Number of ophthalmoscopies and OCT (combined)	1.03	0.02	1.00	1.06	0.03
(B) Variables (year 2)
Country
Canada	0.59	0.64	0.07	5.03	0.63
France	0.86	0.92	0.11	7.02	0.89
Germany	0.60	0.66	0.07	5.16	0.65
Ireland	0.96	1.17	0.09	10.52	0.97
Italy	0.98	1.05	0.12	8.04	0.99
The Netherlands	1.51	1.64	0.18	12.60	0.70
UK	1.17	1.28	0.14	9.97	0.89
Reimbursement type*
Individual	0.88	0.34	0.41	1.88	0.74
National standard	0.74	0.21	0.43	1.29	0.29
Separate contract	0.10	0.11	0.01	0.93	0.04
Unknown	0.63	0.53	0.12	3.23	0.58
Other	0.42	0.48	0.04	3.94	0.45
Age at start of therapy	0.96	0.01	0.94	0.98	<0.001
Baseline visual acuity score	0.97	0.01	0.96	0.97	<0.001
Number of monitoring visits	0.97	0.02	0.94	1.01	0.13
Number of injections (ranibizumab)	1.00	0.02	0.97	1.04	0.85
Number of ophthalmoscopies and OCT (combined)	1.02	0.01	1.00	1.04	0.02

*Reimbursement patient category dropped because of colinearity.
OCT, optical coherence tomography.